Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 4/20 | 0.64 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | APOBEC3B | Q9UH17 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.59 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898383 | 0.87 | APOBEC3G (0.77) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL1898854 | 0.82 | MAPT (0.74) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL1898606 | 0.79 | APOBEC3G (0.63) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL17318569 | 0.78 | NPC1 (0.65) | APOBEC3GMAPTKMT2AMEN1GAA | |
| SCHEMBL1901215 | 0.78 | APOBEC3G (1.00) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL1901939 | 0.78 | CYP2C9 (0.69) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL1898703 | 0.77 | APOBEC3G (0.67) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL1899898 | 0.77 | APOBEC3G (0.56) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 | |
| SCHEMBL8614314 | 0.75 | KMT2A (0.65) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL1901542 | 0.74 | L3MBTL1 (0.73) | APOBEC3GAPOBEC3AMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | APOBEC3G 4852/4885APOBEC3A 4808/4885MAPT 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.